{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:10:14Z","timestamp":1793394614145,"version":"4.5.0"},"reference-count":268,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1053\/j.ajkd.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T03:58:27Z","timestamp":1687319907000},"page":"121-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases"],"prefix":"10.1053","volume":"82","author":[{"suffix":"Jr","given":"Laurence H.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Caster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle N.","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Wadhwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Whittier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 suppl","key":"10.1053\/j.ajkd.2023.02.003_bib1","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1053\/j.ajkd.2016.06.025","article-title":"Timed urine collections for albumin and protein: \u201cThe king is dead, long live the king!\u201d","volume":"68","author":"Rodby","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"10.1053\/j.ajkd.2023.02.003_bib3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJMoa2103753","article-title":"Race, genetic ancestry, and estimating kidney function in CKD","volume":"385","author":"Hsu","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A\u00a0unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"10.1053\/j.ajkd.2023.02.003_bib5","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7326\/M20-4366","article-title":"Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate : a cross-sectional analysis of pooled data","volume":"174","author":"Pottel","year":"2021","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib7","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ndt\/gfv454","article-title":"An estimated glomerular filtration rate equation for the full age spectrum","volume":"31","author":"Pottel","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2215\/CJN.14021118","article-title":"Stopping RAS inhibitors to minimize AKI: more harm than good?","volume":"14","author":"Tomson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"41","key":"10.1053\/j.ajkd.2023.02.003_bib9","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1016\/j.vaccine.2016.08.049","article-title":"Optimizing seroprotection against pneumococcus in children with nephrotic syndrome using the 13-valent pneumococcal conjugate vaccine","volume":"34","author":"Pittet","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1067\/mpd.2003.37","article-title":"Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group","volume":"142","author":"Furth","year":"2003","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","article-title":"Application of the international IgA nephropathy prediction tool one or two years post-biopsy","volume":"102","author":"Barbour","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1053\/j.ajkd.2023.02.003_bib18","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/ajkd.2002.30562","article-title":"Primary IgA nephropathy with low histologic grade and disease progression: is there a \u201cpoint of no return\u201d?","volume":"39","author":"Lai","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib20","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"issue":"19","key":"10.1053\/j.ajkd.2023.02.003_bib22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2023.02.003_bib23","author":"Calliditas Therapeutics"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib24","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"10.1053\/j.ajkd.2023.02.003_bib25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199411033311804","article-title":"A\u00a0controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group","volume":"331","author":"Donadio","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"issue":"24","key":"10.1053\/j.ajkd.2023.02.003_bib27","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib32","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib33","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications","volume":"51","author":"Cattran","year":"1997","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib37","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib39","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1007\/s00467-022-05503-7","article-title":"Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population","volume":"37","author":"Miller","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ki.1978.23","article-title":"Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children","volume":"13","year":"1978","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib42","first-page":"357","article-title":"Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children","volume":"152","author":"Ehrich","year":"1993","journal-title":"Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatr"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-3476(05)82881-1","article-title":"Quantitation of proteinuria with urinary protein\/creatinine ratios and random testing with dipsticks in nephrotic children","volume":"116","author":"Abitbol","year":"1990","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib44","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3476(81)80760-3","article-title":"The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children","volume":"98","year":"1981","journal-title":"J\u00a0Pediatr"},{"key":"10.1053\/j.ajkd.2023.02.003_bib45","doi-asserted-by":"crossref","first-page":"l1800","DOI":"10.1136\/bmj.l1800","article-title":"Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation","volume":"365","author":"Webb","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.2014.240","article-title":"Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome","volume":"87","author":"Sinha","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000045684","article-title":"Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome","volume":"85","author":"Mattoo","year":"2000","journal-title":"Nephron"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/adc.2007.116079","article-title":"Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial","volume":"93","author":"Abeyagunawardena","year":"2008","journal-title":"Arch Dis Child"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib49","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00467-017-3640-5","article-title":"Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome","volume":"32","author":"Abeyagunawardena","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2215\/CJN.01850310","article-title":"Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Gulati","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/jamapediatrics.2021.5189","article-title":"Evaluation of daily low-dose prednisolone during upper respiratory tract infection to prevent relapse in children with relapsing steroid-sensitive nephrotic syndrome: the PREDNOS 2 randomized clinical trial","volume":"176","author":"Christian","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib52","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/cid\/ciaa1044","article-title":"Systematic severe acute respiratory syndrome coronavirus 2 screening at hospital admission in children: a French prospective multicenter study","volume":"72","author":"Poline","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib53","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00467-014-2955-8","article-title":"Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial","volume":"30","author":"Ishikura","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1590\/2175-8239-jbn-2021-0043","article-title":"Persistence of behavioral abnormalities following corticosteroid therapy in children with initial episode of idiopathic nephrotic syndrome: a prospective longitudinal observation","volume":"44","author":"Singh","year":"2022","journal-title":"J\u00a0Bras Nefrol"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib55","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9950","key":"10.1053\/j.ajkd.2023.02.003_bib56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib59","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A\u00a0single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00467-017-3801-6","article-title":"Analysis of 24 genes reveals a monogenic cause in 11.1% of cases with steroid-resistant nephrotic syndrome at a single center","volume":"33","author":"Tan","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000167603","article-title":"Minimal-change glomerulopathy of adulthood","volume":"8","author":"Korbet","year":"1988","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.2014.260","article-title":"A\u00a0multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment","volume":"87","author":"Yoshikawa","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib63","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/ndt\/gft312","article-title":"Rituximab for minimal change disease in adults: long-term follow-up","volume":"29","author":"Bruchfeld","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib64","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfx035","article-title":"Efficacy of mycophenolate treatment in adults with steroid-dependent\/frequently relapsing idiopathic nephrotic syndrome","volume":"10","author":"Sandoval","year":"2017","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib66","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000353898","article-title":"Low birthweight and premature birth are risk factors for podocytopenia and focal segmental glomerulosclerosis","volume":"38","author":"Ikezumi","year":"2013","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2019.09.009","article-title":"Predicting and defining steroid resistance in pediatric nephrotic syndrome using plasma proteomics","volume":"5","author":"Agrawal","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ekir.2019.09.010","article-title":"Predicting and defining steroid resistance in pediatric nephrotic syndrome using plasma metabolomics","volume":"5","author":"Gooding","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.ajkd.2023.02.003_bib70","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2215\/CJN.08750718","article-title":"Integration of genetic testing and pathology for the diagnosis of adults with FSGS","volume":"14","author":"Yao","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib72","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.kint.2018.07.024","article-title":"Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults","volume":"94","author":"Gribouval","year":"2018","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib73","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1681\/ASN.2019020152","article-title":"Contributions of rare gene variants to familial and sporadic FSGS","volume":"30","author":"Wang","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib74","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1016\/j.transproceed.2018.07.010","article-title":"First report of recurrent nephrotic syndrome after kidney transplantation in a patient with NUP93 gene mutations: a case report","volume":"50","author":"Seeman","year":"2018","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib75","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib76","doi-asserted-by":"crossref","first-page":"900","DOI":"10.34067\/KID.0004162021","article-title":"The KIDNEYCODE program: diagnostic yield and clinical features of individuals with chronic kidney disease","volume":"3","author":"Leiberman","year":"2022","journal-title":"Kidney360"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41581-021-00427-1","article-title":"Therapeutic trials in adult FSGS: lessons learned and the road forward","volume":"17","author":"De Vriese","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib78","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib79","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2215\/CJN.07110615","article-title":"Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS","volume":"11","author":"Laurin","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib80","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/ajkd.1998.v32.pm9669427","article-title":"Long-term outcome in children and adults with classic focal segmental glomerulosclerosis","volume":"32","author":"Cattran","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib81","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0272-6386(99)70384-7","article-title":"Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?","volume":"34","author":"Ponticelli","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib82","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","article-title":"Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment","volume":"25","author":"Rydel","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.ackd.2012.02.014","article-title":"Infection-related glomerulonephritis: changing demographics and outcomes","volume":"19","author":"Nast","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ajkd.2023.02.003_bib84","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.ekir.2022.07.163","article-title":"Efficacy of corticosteroids in infection-related glomerulonephritis: a randomized controlled trial","volume":"7","author":"Arivazhagan","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"42","key":"10.1053\/j.ajkd.2023.02.003_bib85","doi-asserted-by":"crossref","first-page":"11941","DOI":"10.3748\/wjg.v21.i42.11941","article-title":"Hepatitis B virus burden in developing countries","volume":"21","author":"Zampino","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"21","key":"10.1053\/j.ajkd.2023.02.003_bib86","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","article-title":"Membranous nephropathy related to hepatitis B virus in adults","volume":"324","author":"Lai","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib87","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12882-018-1154-4","article-title":"Hepatitis B virus infection and\u00a0development of chronic kidney disease: a cohort study","volume":"19","author":"Hong","year":"2018","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib88","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"4-5","key":"10.1053\/j.ajkd.2023.02.003_bib89","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000431331","article-title":"Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy","volume":"41","author":"Xie","year":"2015","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib90","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.kint.2017.11.007","article-title":"Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"93","author":"Swanepoel","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib91","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.kint.2020.01.018","article-title":"The spectrum of kidney biopsy findings in HIV-infected patients in the modern era","volume":"97","author":"Kudose","year":"2020","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib92","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1681\/ASN.2020050558","article-title":"AKI and collapsing glomerulopathy associated with COVID-19 and APOL 1 high-risk genotype","volume":"31","author":"Wu","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib93","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.2020060804","article-title":"COVID-19\u2013associated glomerular disease","volume":"32","author":"Shetty","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib94","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41581-020-0332-3","article-title":"COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19","volume":"16","author":"Velez","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib95","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-021-00242-0","article-title":"The glomerular filtration barrier: a structural target for novel kidney therapies","volume":"20","author":"Daehn","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib96","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A\u00a0trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Donel","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib97","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib98","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib99","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1523-1755.2004.00865.x","article-title":"The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection","volume":"66","author":"Szczech","year":"2004","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib100","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2215\/CJN.10991012","article-title":"Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy","volume":"8","author":"Foy","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib101","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1093\/ndt\/gfr702","article-title":"The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations","volume":"27","author":"Wearne","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib102","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","article-title":"Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification","volume":"31","author":"Sethi","year":"2011","journal-title":"Semin Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib103","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2014a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib104","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/ndt\/gfs288","article-title":"Idiopathic membranoproliferative glomerulonephritis: does it exist?","volume":"27","author":"Fervenza","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib105","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib106","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2215\/CJN.06760909","article-title":"Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy","volume":"5","author":"Sethi","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib107","first-page":"165","article-title":"Membranoproliferative glomerulonephritis associated with autoimmune diseases","volume":"27","author":"Zand","year":"2014","journal-title":"J\u00a0Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib108","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib109","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years\u2019 experience at Mayo Clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.2012.212","article-title":"C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib111","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group [published correction appears in Nat Rev Nephrol. 2019;15(2):121]","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib112","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.kint.2021.02.038","article-title":"Immunofluorescence staining for immunoglobulin heavy chain\/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases","volume":"100","author":"Nasr","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib113","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib114","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.kint.2020.03.025","article-title":"Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic\/Renal Pathology Society Working Group","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib116","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-0034-1375701","article-title":"Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Sethi","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2023.02.003_bib117","article-title":"Treatment of non-amyloid monoclonal gammopathies of renal significance (MGRS) with\u00a0clone directed therapies-single center experience","volume":"134","author":"Bhutani","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib118","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1053\/j.ajkd.2019.03.355","article-title":"Membranoproliferative glomerulonephritis responsive to corticosteroids associated with Sjogren\u2019s syndrome and hepatitis C","volume":"73","author":"Skaria","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib119","first-page":"51","article-title":"HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies","volume":"78","author":"Garini","year":"2007","journal-title":"Acta Biomed"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib120","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2217\/imt-2018-0031","article-title":"Rituximab treatment for immune-complex-mediated membranoproliferative glomerulonephritis","volume":"10","author":"Lu","year":"2018","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib121","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib122","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib123","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: core curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib124","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","article-title":"Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays","volume":"76","author":"Damoiseaux","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib125","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib126","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1)(suppl 75","key":"10.1053\/j.ajkd.2023.02.003_bib127","first-page":"S32","article-title":"Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis","volume":"31","author":"Poulton","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13023-021-01794-5","article-title":"Diagnostic delays in vasculitis and factors associated with time to diagnosis","volume":"16","author":"Sreih","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2014a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib131","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib132","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib133","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/art.40538","article-title":"Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: subgroup analysis of nationwide prospective cohort studies","volume":"70","author":"Watanabe","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib134","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.40776","article-title":"Effect of disease activity at three and six months after diagnosis on long-term outcomes in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Gopaluni","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/ki.2013.24","article-title":"Antineutrophil cytoplasm antibody-associated vasculitis: recent developments","volume":"84","author":"Furuta","year":"2013","journal-title":"Kidney Int. Aug"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib136","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib137","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib138","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib139","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib140","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib141","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib142","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib143","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib144","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib146","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib147","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib148","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3899\/jrheum.201330","article-title":"ANCA-associated vasculitis management in the United States: data from the Rheumatology Informatics System for Effectiveness (RISE) Registry","volume":"48","author":"Wallace","year":"2021","journal-title":"J\u00a0Rheumatol"},{"issue":"19","key":"10.1053\/j.ajkd.2023.02.003_bib149","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. Comparative Study Multicenter Study Randomized Controlled Trial","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib150","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"suppl 10","key":"10.1053\/j.ajkd.2023.02.003_bib151","article-title":"A\u00a0randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract #806]","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib152","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib153","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Gulati","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib154","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib155","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib156","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2215\/CJN.03190321","article-title":"Disease activity and adverse events in patients with ANCA-associated vasculitides undergoing long-term dialysis","volume":"16","author":"Kauffmann","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"10.1053\/j.ajkd.2023.02.003_bib157","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jama.2021.13879","article-title":"Reduced-dose vs high-dose glucocorticoids added to rituximab and remission induction in ANCA-associated vasculitis [reply]","volume":"326","author":"Furuta","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib158","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2023.02.003_bib159","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline","volume":"376","author":"Zeng","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050507","article-title":"Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review","volume":"12","author":"Xiao","year":"2022","journal-title":"BMJ Open"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib161","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib162","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib163","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib164","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib165","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates\u00a0in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib166","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ekir.2019.01.004","article-title":"Understanding long-term remission off therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"4","author":"Hogan","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib167","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse\u00a0of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib168","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","article-title":"Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts","volume":"58","author":"Pagnoux","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib169","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib170","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib171","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib172","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","article-title":"Relapse in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis","volume":"5","author":"Salama","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib173","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/keaa667","article-title":"Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies","volume":"60","author":"He","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib174","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib175","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib176","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib177","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib178","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ccm.2019.05.012","article-title":"Update on the management of respiratory manifestations of the antineutrophil cytoplasmic antibodies-associated vasculitides","volume":"40","author":"Thompson","year":"2019","journal-title":"Clin Chest Med"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib179","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3899\/jrheum.191042","article-title":"Clinical characteristics and prognostic analysis of microscopic polyangiitis with diffuse alveolar hemorrhage","volume":"48","author":"Tang","year":"2021","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ajkd.2023.02.003_bib180","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2023.02.003_bib181","doi-asserted-by":"crossref","unstructured":"Geetha D, Eirin A, True K, et\u00a0al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation. 27 91(12):1370-1375. https:\/\/doi.org\/10.1097\/TP.0b013e31821ab9aa","DOI":"10.1097\/TP.0b013e31821ab9aa"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib182","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1093\/ndt\/gfp347","article-title":"Renal transplantation in systemic vasculitis: when is it safe?","volume":"24","author":"Little","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib183","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ctr.12084","article-title":"Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation","volume":"27","author":"Marco","year":"2013","journal-title":"Clin Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib184","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1093\/rheumatology\/keac067","article-title":"High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership","volume":"61","author":"Carlucci","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib185","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ekir.2020.04.005","article-title":"Low-grade proteinuria does not exclude significant kidney injury in lupus nephritis","volume":"5","author":"De Rosa","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib186","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2023.02.003_bib187","first-page":"149","article-title":"Studies of carcinogenicity in the rate of derivatives of aromatic amines related to N-2-fluorenylacetamide","volume":"24","author":"Morris","year":"1960","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib188","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41433-018-0136-x","article-title":"The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary","volume":"32","author":"Yusuf","year":"2018","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib189","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib190","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-020-01380-2","article-title":"The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary","volume":"35","author":"Yusuf","year":"2021","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib191","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0b013e31817a7e30","article-title":"Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature","volume":"14","author":"Gupta","year":"2008","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib192","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib193","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.autrev.2005.10.001","article-title":"Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study","volume":"5","author":"Manger","year":"2006","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib194","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.40079","article-title":"Brief report: the Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-mullerian hormone","volume":"69","author":"Tamirou","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0002-9343(77)90345-X","article-title":"Lupus nephritis: clinical course as related to morphologic forms and their transitions","volume":"62","author":"Baldwin","year":"1977","journal-title":"Am J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib196","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.ackd.2019.08.015","article-title":"The kidney biopsy in systemic lupus erythematosus: a view of the past and a vision of the future","volume":"26","author":"Ayoub","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2023.02.003_bib197","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.transproceed.2008.07.041","article-title":"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders","volume":"40","author":"Darji","year":"2008","journal-title":"Transplant Proc"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib198","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2215\/CJN.02670409","article-title":"Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option","volume":"4","author":"McKinley","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib199","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000319641","article-title":"Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?","volume":"117","author":"Hebert","year":"2011","journal-title":"Nephron Clin Prac"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib200","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2023.02.003_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.622225","article-title":"The use of glucocorticoids in lupus nephritis: new pathways for an old drug","volume":"8","author":"Mejia-Vilet","year":"2021","journal-title":"Front Med"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib202","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/0961203319842924","article-title":"Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies","volume":"28","author":"Dall\u2019Era","year":"2019","journal-title":"Lupus"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib203","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard.46.10.773","article-title":"A\u00a0double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment","volume":"46","author":"Edwards","year":"1987","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib204","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","article-title":"Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts","volume":"16","author":"Ruiz-Irastorza","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"10289","key":"10.1053\/j.ajkd.2023.02.003_bib205","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib206","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A\u00a0randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib207","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib208","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib209","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib211","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.39067","article-title":"Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America","volume":"67","author":"Wofsy","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib212","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2215\/CJN.03290412","article-title":"Lupus nephritis: induction therapy in severe lupus nephritis\u2014should MMF be considered the drug of choice?","volume":"8","author":"Rovin","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib213","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"33","key":"10.1053\/j.ajkd.2023.02.003_bib214","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021121","article-title":"Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis: a PRISMA-compliant meta-analysis","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib216","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib217","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib218","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5414\/CN109325","article-title":"Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus","volume":"89","author":"Yang","year":"2018","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib219","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: a systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1053\/j.ajkd.2023.02.003_bib220","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","article-title":"Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis","volume":"79","author":"Mok","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib221","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2021.06.036","article-title":"How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not","volume":"100","author":"Van Gelder","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib222","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2215\/CJN.13030921","article-title":"The cost effectiveness of belimumab and voclosporin for patients with lupus nephritis in the United States","volume":"17","author":"Mandrik","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib223","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment With Rituximab Study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1053\/j.ajkd.2023.02.003_bib224","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1053\/j.ajkd.2023.02.003_bib225","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Mendez","year":"2018","journal-title":"Clin J Am Soc Nephro"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib226","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A\u00a04-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment\u2014clinical response compared to literature and immunological re-assessment","volume":"14","author":"Roccatello","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib227","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1053\/j.ajkd.2023.02.003_bib228","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib229","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.41608","article-title":"The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model","volume":"73","author":"Marinov","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib231","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib232","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib233","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A\u00a0proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN nephritis trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib234","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000213","article-title":"Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?","volume":"4","author":"Ugolini-Lopes","year":"2017","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib235","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A\u00a0secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib236","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib237","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus : a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib238","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib239","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/03009742.2014.887769","article-title":"Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity","volume":"43","author":"Sjowall","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib240","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.semarthrit.2016.09.006","article-title":"New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab","volume":"46","author":"Staveri","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"20","key":"10.1053\/j.ajkd.2023.02.003_bib241","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N\u00a0Engl\u00a0J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib242","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib243","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib244","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/j.ajkd.2008.03.036","article-title":"Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy","volume":"52","author":"Camous","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"4 suppl 78","key":"10.1053\/j.ajkd.2023.02.003_bib245","first-page":"S75","article-title":"What happens after complete withdrawal of therapy in patients with lupus nephritis","volume":"31","author":"Moroni","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib246","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/rheumatology\/kes293","article-title":"Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis","volume":"52","author":"Yap","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1053\/j.ajkd.2023.02.003_bib247","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib248","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"Anders","year":"2020","journal-title":"Lupus nephritis. Nat Rev Dis Primers"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib249","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib250","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A\u00a0prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib251","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib252","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.ackd.2019.08.013","article-title":"Pregnancy in women with\u00a0systemic lupus and lupus nephritis","volume":"26","author":"Maynard","year":"2019","journal-title":"Adv Chronic Kidney\u00a0Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2023.02.003_bib253","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.rdc.2021.04.008","article-title":"Management of pregnancy in lupus","volume":"47","author":"Moyer","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"issue":"12","key":"10.1053\/j.ajkd.2023.02.003_bib254","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2021.14781","article-title":"Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement","volume":"326","author":"Davidson","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib255","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1177\/0961203314540353","article-title":"Tacrolimus is an effective treatment for lupus nephritis in pregnancy","volume":"23","author":"Webster","year":"2014","journal-title":"Lupus"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib256","first-page":"249","article-title":"Identification of the Goodpasture antigen, alpha 3(IV) NC1, and 4 other NC1 domains of type IV collagen, by amino-terminal sequence analysis of human glomerular basement membrane separated by two-dimensional electrophoresis","volume":"2","author":"Derry","year":"1994","journal-title":"Exp Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib257","first-page":"355","article-title":"Tissue-specific distribution of the Goodpasture antigen demonstrated by 2-D electrophoresis and Western blotting","volume":"9","author":"Derry","year":"1994","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib258","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1053\/ajkd.2002.33385","article-title":"Goodpasture\u2019s disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques","volume":"39","author":"Salama","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib259","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib260","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2021111460","article-title":"Endopeptidase cleavage of anti-glomerular basement membrane antibodies in\u00a0vivo in severe kidney disease: an open-label phase 2a study","volume":"33","author":"Uhlin","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6516","key":"10.1053\/j.ajkd.2023.02.003_bib261","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/bmj.292.6516.301","article-title":"Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4","volume":"292","author":"Savage","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"5","key":"10.1053\/j.ajkd.2023.02.003_bib262","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8364","key":"10.1053\/j.ajkd.2023.02.003_bib263","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(83)90923-6","article-title":"Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane","volume":"2","author":"Donaghy","year":"1983","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ajkd.2023.02.003_bib264","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12882-018-1038-7","article-title":"Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease","volume":"19","author":"Heitz","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2023.02.003_bib266","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2015.04.003","article-title":"Rituximab in anti-GBM disease: a retrospective study of 8 patients","volume":"60","author":"Touzot","year":"2015","journal-title":"J\u00a0Autoimmun"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib267","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/15.6.920","article-title":"Goodpasture\u2019s syndrome treated with mycophenolate mofetil","volume":"15","author":"Garcia-Canton","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2023.02.003_bib268","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2169\/internalmedicine.49.2321","article-title":"Successful treatment of resistant antiglomerular basement membrane antibody positivity with mycophenolic acid","volume":"49","author":"Kiykim","year":"2010","journal-title":"Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.02.003_bib269","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5414\/CN107333","article-title":"Anti-glomerular basement membrane disease treated with mycophenolate mofetil, corticosteroids, and plasmapheresis","volume":"80","author":"Mori","year":"2013","journal-title":"Clin Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2023.02.003_bib270","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/j.1600-6143.2006.01502.x","article-title":"Recurrent glomerulonephritis after kidney transplantation","volume":"6","author":"Choy","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2023.02.003_bib271","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/IJNRD.S150539","article-title":"Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation","volume":"11","author":"Kashtan","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623005917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623005917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:47:51Z","timestamp":1759463271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638623005917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":268,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0272638623005917"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.02.003","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}